Search Results for "Brilinta Sales"

02:31 EDT 25th April 2015 | BioPortfolio

Matching Channels

Brilinta (TM) - ticagrelor, AstraZeneca's new heart drug

Brilinta - ticagrelor, AstraZeneca's new heart drug is a blood-thinning medicine designed to prevent dangerous blood clots in patients with serious chest pain or previous heart attacks. It re...

Sales Jobs

Pfizer

Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have ...

Boehringer Ingelheim

Boehringer Ingelheim is a global pharmaceutical company with annual sales of over $16 billion, making it the 10th largest pharmaceutical company in the world based on sales.  With bases in 47 c...

Plavix

Plavix is a clot-busting drug, produced by Bristol-Myers Squibb Company, and reached annual sales in 2009 of $4.2m, making the third highest drug in the world (based on 2009 annual sales). Prescri...

Matching News

Mixed results for AstraZeneca in high-profile Brilinta study

Experts say AstraZeneca is at risk of ‘diminishing returns’ in the clinical advantages of its blood-thinning drug Brilinta, after it showed mixed results in a post heart attack trial. A large outc...

AstraZeneca’s troubled Brilinta gets welcome lift

AstraZeneca has reported positive primary endpoint results for its anti-clogging drug Brilinta to treat patients who have had a heart attack or severe chest pains. Clinical trials involving over 21,00...

AZ unveils Brilinta data, seeks label extension

AstraZeneca plc (LSE:AZN; NYSE:AZN) revealed new details from a 21,000-patient CV outcomes study showing that long-term use of the anticoagulant Brilinta ticagrelor reduced the incidence of major thro...

ACC 2015: AstraZeneca optimistic on Brilinta after PEGASUS, others less so

AstraZeneca's US president Paul Hudson is optimistic about the opportunities for Brilinta (ticagrelor) in longer-term treatment of acute coronary syndrome (ACS) based on results from the Phase III PEG...

FDA Approves New Crushing Option for the Administration of Brilinta

March 30, 2015 -- AstraZeneca (NYSE: AZN) today announced that the US Food and Drug Administration (FDA) has approved a new administration option for acute coronary syndrome (ACS) patients who are una...

AstraZeneca: FDA Approves New Administration Option For BRILINTA

LONDON (dpa-AFX) - AstraZeneca (AZN) announced the US FDA has approved a new administration option for acute coronary syndrome patients who are unable to swallow BRILINTA 90 mg tablets whole. The ...

AstraZeneca developing reversal agent for blood-thinner Brilinta

LONDON, Nov 13 (Reuters) - AstraZeneca is developing an antibody treatment to rapidly reverse the blood-thinning effects of its heart drug Brilinta in rare emergency situations, such as urgent surgery...

AstraZeneca study of Brilinta meets primary endpoint

Anglo-Swedish drug major AstraZeneca has announced its PEGASUS-TIMI 54 study of Brilinta (ticagrelor) has met its primary endpoint.

Matching PubMed Articles

Understanding Community Norms Surrounding Tobacco Sales.

In the US, denormalizing tobacco use is key to tobacco control; less attention has been paid to denormalizing tobacco sales. However, some localities have placed limits on the number and type of retai...

Retail Impact of Raising Tobacco Sales Age to 21 Years.

The majority of tobacco use emerges in individuals before they reach 21 years of age, and many adult distributors of tobacco to youths are young adults aged between 18 and 20 years. Raising the tobacc...

The total sale of prescription drugs with an abuse potential predicts the number of excessive users: a national prescription database study.

Prescription drug sales may vary considerably across regions and over time. This study aimed to assess whether there is an association between mean drug sales and prevalence of excessive use in a rang...

Is local alcohol outlet density related to alcohol-related morbidity and mortality in Scottish cities?

Alcohol consumption may be influenced by the local alcohol retailing environment. This study is the first to examine neighbourhood alcohol outlet availability (on- and off-sales outlets) and alcohol-r...

Higher Price, Fewer Packs: Evaluating a Tobacco Tax Increase With Cigarette Sales Data.

In 2013, Minnesota increased cigarette taxes by $1.75, the largest US state increase since 2000. We obtained convenience store data of cigarette sales from January 2012 to December 2013 from the Niels...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement